164名患有NRAS突变非小细胞肺癌 (NSCLC) 的患者的表征
Agathe Dehem1, Julien Mazieres2, Ali Chour3
1Univ. Lille, CHU Lille, Thoracic Oncology Department, F-59000 Lille, France.
Lung cancer (Amsterdam, Netherlands)
|October 15, 2023
概括
这项研究详细介绍了NRAS突变的非小细胞肺癌 (NSCLC) 的结果,这是一个罕见的子集. 组合疗法显示出有前途的响应率,需要在NSCLC患者中进一步调查.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 肺部病理学 肺部病理学
背景情况:
- 在非小细胞肺癌 (NSCLC) 中,NRAS突变很罕见,占病例的不到1%.
- 对于这种特定的NSCLC子集,临床数据有限,之前没有关于化疗或免疫检查点抑制剂 (ICI) 治疗反应的报道.
研究的目的:
- 分析NRAS突变NSCLC患者的临床特征和治疗结果.
- 在这种罕见的患者群体中,评估包括化疗和ICI在内的全身治疗的疗效.
主要方法:
- 在14个法国中心对164名NRAS突变NSCLC患者的回顾性分析 (2014年8月 - 2020年11月).
- 从医疗记录中收集和审查临床和分子数据.
- 生存分析和治疗响应率的评估 (客观响应率,无进展生存率).
主要成果:
- 队列 (63.4%的第四阶段) 的平均年龄为62岁,腺癌是最常见的组织学 (81.7%).
- NRAS突变主要在编码子61 (70%) 中发现. 第四阶段患者的平均整体存活时间为15.3个月.
- 治疗以白金为基础的双倍,ICI或组合疗法显示的客观响应率分别为45%,35%和70%,相应的无进展生存期中位数为5.8,6.9和8.6个月.
结论:
- 经NRAS突变的NSCLC与吸烟史和代码子61突变的高患病率有关.
- 免疫疗法和化疗的结合显示出令人鼓舞的结果,表明这种治疗策略在NRAS突变NSCLC中的潜在疗效.
更多相关视频
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.4K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.0K
相关概念视频
02:38The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:03Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K